Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.59 |
| ▸ | HRH1 | P35367 | 14/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | HTR7 | P34969 | 4/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1E | P28566 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13654438 | 0.91 | HTR6 (0.51) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL2185986 | 0.89 | HTR6 (0.57) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3025373 | 0.88 | HTR6 (0.60) | HTR6HRH1 | |
| SCHEMBL3025293 | 0.87 | HTR6 (0.59) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3024587 | 0.87 | HTR6 (0.59) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3033531 | 0.87 | HTR6 (0.49) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL13343203 | 0.86 | HTR6 (0.61) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3029077 | 0.85 | HTR6 (0.53) | HTR6HRH1ADRA2AHTR2AHTR2C | |
| SCHEMBL3032444 | 0.85 | HRH1 (0.58) | HTR6HRH1ADRA2AHTR2AHTR7 | |
| SCHEMBL3785040 | 0.85 | HTR6 (0.47) | HTR6HRH1ADRA2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2019-08-01 | — | — | US | disclosed |
| US-9655886-B2 | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-05-23 | — | — | US | disclosed |
| US-9655886-B2 | Substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, methods for use thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-05-23 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-01-05 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| EP-2346332-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | Medivation Technologies, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100120792-A1 | Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof | ALLA CHEM, LLC | 2010-05-13 | — | — | US | disclosed |
| WO-2010051501-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010051501-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| EP-2145887-A2 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008123796-A2 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | HTR6 47/4885HRH1 93/4885ADRA2A 11/4885 |
| US-20100120792-A1 | Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof | HTR3C, HTR3A, HTR6 | HTR6 3/4885HRH1 75/4885ADRA2A 207/4885 |
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | ADORA3, HTR3C, TRPV3 | HTR6 6/4885HRH1 139/4885ADRA2A 154/4885 |
| US-20170000773-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | HTR6, HTR3C, HTR3B | HTR6 1/4885HRH1 145/4885ADRA2A 200/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | HTR6 13/4885HRH1 537/4885ADRA2A 136/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | HTR6 85/4885HRH1 188/4885ADRA2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.